JAMA Oncology

JAMA Oncology(英文缩写 JAMA ONCOL),ISSN 2374-2437,eISSN 2374-2445 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。

发文量统计区间：2025-09-21 至 2026-09-21，按本站收录文献的发表日期统计。

指标来源：jcr_cas_ifqb

历年影响因子趋势

JAMA Oncology 最新收录文献

1. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   1. Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?

   PMID:

   42752789

   作者:

   Kyunghee Burkitt, Barbara A Burtness

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3459

   日期:

   2026-09-17

   查看详情PubMed 原文记录
2. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   2. Symptom Trajectories and Use of Medical Assistance in Dying Among Adolescent and Young Adults With Cancer.

   PMID:

   42752764

   作者:

   Koichiro Yuji

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3755

   日期:

   2026-09-17

   查看详情PubMed 原文记录
3. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   3. Trends in Prebiopsy MRI Utilization for Prostate Cancer Detection.

   PMID:

   42752749

   作者:

   Stephen Rhodes, Spyridon P Basourakos, Jim C Hu, Christopher E Barbieri, Angela Y Jia, Soumyajit Roy, Daniel E Spratt, Lee Ponsky, Jonathan E Shoag

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3620

   日期:

   2026-09-17

   查看详情PubMed 原文记录
4. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   4. Symptom Trajectories and Use of Medical Assistance in Dying Among Adolescent and Young Adults With Cancer-Reply.

   PMID:

   42752744

   作者:

   Miranda M Fidler-Benaoudia

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3758

   日期:

   2026-09-17

   查看详情PubMed 原文记录
5. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   5. Melding Structured Care With Improvisation-Jazz in Medicine.

   PMID:

   42752737

   作者:

   Anna Clebone Ruskin, Keith J Ruskin, Lawrence B Marks

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3376

   日期:

   2026-09-17

   查看详情PubMed 原文记录
6. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   6. Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score Less Than 1: A Bayesian Meta-Analysis.

   PMID:

   42752536

   作者:

   Meile Jin, Songchen Shi, Zhonghui Li, Shasha Xing, Jinwen Wang, Fujun Han

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3626

   日期:

   2026-09-17

   Immune checkpoint inhibitors (ICIs) are recommended for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), including patients with tumors with a programmed cell death 1 ligand 1 (PD-L1) combined positive score (CPS) of less than 1. However, the benefit of ICIs in this population rem…

   查看详情PubMed 原文记录
7. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   7. PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

   PMID:

   42752531

   作者:

   Jared Weiss, John Kaczmar, Ashish Chintakuntlawar, Francis P Worden, Ranee Mehra, Hyunseok Kang, Ralph G Zinner, Susanne M Arnold, Priyanka Bhateja, Kevin Harrington, Shilpi Gupta, Yujie Zhao, Dahn C Pham, Sidra Najeeb, Varinder Kaur, Ammar Sukari, Anshu Giri, Timothy J Panella, Jaspreet Grewal, Barbara Galligan, Eric Nadler, Cliona Grant, Rafael Arteta-Bulos, David J Noble, David Schaaf, Katharine A R Price

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3492

   日期:

   2026-09-17

   The incidence of human papillomavirus type 16 (HPV16-positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. To determine the efficacy and safety of a therapeutic HPV16-targeted immunotherapy…

   查看详情PubMed 原文记录
8. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   8. Management of Soft Tissue and Visceral Leiomyosarcomas.

   PMID:

   42720945

   作者:

   Fernando Campos, Rebecca Gladdy, Annie Achee, Mitch Achee, Kenneth Cardona, Joseph Carlson, Tom Wei-Wu Chen, Priya Chudasama, Elizabeth A Connolly, Angelo P Dei Tos, Josephine K Dermawan, Chiara Fabbroni, B Ashleigh Guadagnolo, Elise Nassif Haddad, Matthew L Hemming, Paul Huang, Robin L Jones, Alexander J Lazar, Alessandra Maleddu, Aisha B Miah, Scott Okuno, Joanna Przybyl, Chandrajit P Raut, Albiruni Abdul Razak, Denise Reinke, Roberta Sanfilippo, Paul Savage, Kathrin Schuster, Gerard Van Oortmerssen, Alessandro Gronchi, Bernd Kasper

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3366

   日期:

   2026-09-10

   Leiomyosarcoma is a rare and heterogeneous malignant mesenchymal neoplasm associated with substantial morbidity and mortality. Given recent advances in biologic understanding and the complexity of leiomyosarcoma, a consensus-driven approach is needed to harmonize management and address remaining cli…

   查看详情PubMed 原文记录
9. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

   9. Cancer Didn't Teach Me Much.

   PMID:

   42720941

   作者:

   Christina Karaoli Taylor

   期刊:

   JAMA oncology PubMed

   DOI:

   10.1001/jamaoncol.2026.3326

   日期:

   2026-09-10

   查看详情PubMed 原文记录
10. JCR分区: Q1 CAS分区: B1 影响因子: 23.9

    10. Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.

    PMID:

    42720936

    作者:

    Kosei Hasegawa, Nicoletta Colombo, Krishnansu S Tewari, Coraline Dubot, M Valeria Cáceres, Domenica Lorusso, Ronnie Shapira-Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüs, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Erin Jensen, Sarper Toker, Bradley J Monk

    期刊:

    JAMA oncology PubMed

    DOI:

    10.1001/jamaoncol.2026.3547

    日期:

    2026-09-10

    In the KEYNOTE-826 study, pembrolizumab (vs placebo) plus platinum-based chemotherapy (with or without bevacizumab) significantly improved progression-free survival and overall survival in participants with previously untreated persistent, recurrent, or metastatic cervical cancer at interim analysis…

    查看详情PubMed 原文记录